FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253440104> ?p ?o ?g. }

• W4253440104 endingPage "S3" @default.
• W4253440104 startingPage "S3" @default.
• W4253440104 abstract "Abstract Background Both infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel disease (IBD) in adults. VDZ is gut-specific and thought to be less effective in controlling extraintestinal manifestations than IFX. The purpose of this study was to compare the incidence and timing of arthralgias between IFX and VDZ. Methods We performed a retrospective cohort study of bio-naïve adult patients treated with IFX or VDZ for ulcerative colitis (UC) or Crohn’s disease (CD) at a large multicenter gastroenterology private practice. Patients were case-matched 1:1 based on age, gender, diagnosis, and baseline disease severity using the partial Mayo (pMayo) for UC and the modified Harvey-Bradshaw Index (mHBI) for CD. Arthralgias were captured out to 12 months of therapy and classified as pre-existing or new-onset based on time to occurrence. Those with pre-existing arthralgias were excluded from new-onset arthralgias analyses. Rates of arthralgias and time to new-onset arthralgias were compared between IFX and VDZ patients. Results A total of 77 IFX (58 UC, 19 CD) and 77 VDZ (58 UC, 19 CD) case-matched pairs were generated. Baseline demographics were similar between IFX and VDZ groups: mean age 45±16.9 vs 46±16.2, male gender 60% vs 61%. Rates of pre-existing arthralgias were 13/77 (17%) and 12/77 (16%) in IFX and VDZ cohorts (p=0.83), respectively. Resolution of pre-existing arthralgias was also similar between groups (6/13 vs 7/12, p=0.70). Of the remaining 64 IFX and 65 VDZ patients without arthralgias at baseline, 16 (25%) IFX patients and 17 (26%) VDZ patients experienced new-onset arthralgias (p=1.0). Median time to new-onset arthralgias was 5.0 (IQR 3.4–7.0) months in IFX patients, compared to 3.3 (IQR 1.4–5.3) months in VDZ patients (p=0.15). While VDZ patients appeared to develop new-onset arthralgias earlier, this was not significant (p=0.20) [Figure 1]. Of note, two IFX patients discontinued therapy due to suspected drug-induced lupus with arthralgias; there were no VDZ discontinuations due to arthralgias. Conclusions Our data suggests that resolution of pre-existing arthralgias and new-onset arthralgias are similar, despite the gut selectivity of VDZ compared to IFX. Additionally, there was no difference in overall time to new-onset arthralgias. These data need to be verified in a larger cohort." @default.
• W4253440104 created "2022-05-12" @default.
• W4253440104 creator A5012002966 @default.
• W4253440104 creator A5023434723 @default.
• W4253440104 creator A5045834603 @default.
• W4253440104 creator A5080385781 @default.
• W4253440104 date "2020-01-01" @default.
• W4253440104 modified "2023-09-28" @default.
• W4253440104 title "P100 REAL-WORLD COMPARISON OF ARTHRALGIAS WITH INFLIXIMAB VS. VEDOLIZUMAB IN THE TREATMENT OF BIO-NAIVE INFLAMMATORY BOWEL DISEASE" @default.
• W4253440104 doi "https://doi.org/10.1093/ibd/zaa010.006" @default.
• W4253440104 hasPublicationYear "2020" @default.
• W4253440104 type Work @default.
• W4253440104 citedByCount "0" @default.
• W4253440104 crossrefType "journal-article" @default.
• W4253440104 hasAuthorship W4253440104A5012002966 @default.
• W4253440104 hasAuthorship W4253440104A5023434723 @default.
• W4253440104 hasAuthorship W4253440104A5045834603 @default.
• W4253440104 hasAuthorship W4253440104A5080385781 @default.
• W4253440104 hasBestOaLocation W42534401041 @default.
• W4253440104 hasConcept C126322002 @default.
• W4253440104 hasConcept C141071460 @default.
• W4253440104 hasConcept C144024400 @default.
• W4253440104 hasConcept C149923435 @default.
• W4253440104 hasConcept C2776207728 @default.
• W4253440104 hasConcept C2777138892 @default.
• W4253440104 hasConcept C2778260677 @default.
• W4253440104 hasConcept C2779134260 @default.
• W4253440104 hasConcept C2779280984 @default.
• W4253440104 hasConcept C2780084366 @default.
• W4253440104 hasConcept C2780479503 @default.
• W4253440104 hasConcept C71924100 @default.
• W4253440104 hasConcept C72563966 @default.
• W4253440104 hasConcept C90924648 @default.
• W4253440104 hasConceptScore W4253440104C126322002 @default.
• W4253440104 hasConceptScore W4253440104C141071460 @default.
• W4253440104 hasConceptScore W4253440104C144024400 @default.
• W4253440104 hasConceptScore W4253440104C149923435 @default.
• W4253440104 hasConceptScore W4253440104C2776207728 @default.
• W4253440104 hasConceptScore W4253440104C2777138892 @default.
• W4253440104 hasConceptScore W4253440104C2778260677 @default.
• W4253440104 hasConceptScore W4253440104C2779134260 @default.
• W4253440104 hasConceptScore W4253440104C2779280984 @default.
• W4253440104 hasConceptScore W4253440104C2780084366 @default.
• W4253440104 hasConceptScore W4253440104C2780479503 @default.
• W4253440104 hasConceptScore W4253440104C71924100 @default.
• W4253440104 hasConceptScore W4253440104C72563966 @default.
• W4253440104 hasConceptScore W4253440104C90924648 @default.
• W4253440104 hasIssue "Supplement_1" @default.
• W4253440104 hasLocation W42534401041 @default.
• W4253440104 hasOpenAccess W4253440104 @default.
• W4253440104 hasPrimaryLocation W42534401041 @default.
• W4253440104 hasRelatedWork W1576589857 @default.
• W4253440104 hasRelatedWork W2187503363 @default.
• W4253440104 hasRelatedWork W2794344940 @default.
• W4253440104 hasRelatedWork W3205942131 @default.
• W4253440104 hasRelatedWork W4226137497 @default.
• W4253440104 hasRelatedWork W4226253339 @default.
• W4253440104 hasRelatedWork W4282048809 @default.
• W4253440104 hasRelatedWork W4310184611 @default.
• W4253440104 hasRelatedWork W52633626 @default.
• W4253440104 hasRelatedWork W79702259 @default.
• W4253440104 hasVolume "26" @default.
• W4253440104 isParatext "false" @default.
• W4253440104 isRetracted "false" @default.
• W4253440104 workType "article" @default.